The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients
Open accessAbstract
T-cell receptor (TCR) delta gene rearrangements are observed in more than 80% of acute lymphoblastic leukemia (ALL) patients. Moreover, a preferential usage of specific genetic elements has been shown in different ALL subtypes: V delta 1 DJ delta 1 rearrangements predominate in T-ALL, while most B-precursor ALLs show a recombination of V delta 2 to D delta 3. Recently we have proposed a strategy for the detection of minimal residual disease (MRD) based on the isolation of clonospecific probes following the in vitro amplification of V delta 1 DJ delta 1 junctions by polymerase chain reaction (PCR) and now have adapted this method to the preparation of specific V delta 2 D delta 3 fragments. In the present study, clonospecific probes were generated from 11 T-ALL and 16 cALL patients (21 children, 6 adults). The sensitivity of these 27 probes in detecting residual leukemia cells varied between 10(-4) to 10(-6) as determined by semiquantitative evaluation of dilution experiments. PCR analysis of 55 bone marrow (BM) and peripheral blood (PB) samples obtained from the 27 patients during complete clinical remission showed the following results: (1) Evidence for MRD was obtained in the BM of all patients (eight of eight) investigated 2 to 6 months after remission induction and also in 6 of 11 cases on maintenance therapy 7 to 19 months after diagnosis. (2) In contrast, all patients but one (10 of 11) analyzed 6 to 41 months after the termination of treatment lacked apparent evidence for leukemia DNA; the exception was a girl exhibiting 10(-4) to 10(-5) residual cells in her PB 5.5 years after diagnosis. (3) Longitudinal analysis in nine patients disclosed marked individual differences in the intervals between achievement of clinical remission and complete eradication of the leukemia cell clone. (4) Differences in the duration of MRD were not associated with distinct clinical-hematologic features. (5) Detection of residual disease by PCR proceeded clinical relapse in two cases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primer-Directed Enzymatic Amplification of DNA with a Thermostable DNA Polymerase
Saiki, R. K., Gelfand, D. H., Stoffel, S., Scharf, S. J., Higuchi, R., Horn, G. T., Mullis, K. B., & Erlich, H. A. (1988) · Science · doi:10.1126/science.2448875 · Cited by 17,719
Cited by
Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia
Cavé, H., van der Werff ten Bosch, J., Suciu, S., Guidal, C., Waterkeyn, C., Otten, J., Bakkus, M., Thielemans, K., Grandchamp, B., Vilmer, E., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390904 · Cited by 768
Schrappe, M., Reiter, A., Ludwig, W. D., Harbott, J., Zimmermann, M., Hiddemann, W., Niemeyer, C. M., Henze, G., Feldges, A., Zintl, F., et al. (2000) · PubMed · doi:10.1182/blood.v95.11.3310 · Cited by 602
Self-citationSchrappe, M., Reiter, A., Zimmermann, M., Harbott, J., Ludwig, W.-D., Henze, G., Gadner, H., Odenwald, E., & Riehm, H. (2000) · Leukemia · doi:10.1038/sj.leu.2401973 · Cited by 531
Self-citationRombouts, W., Blokland, I., Löwenberg, B., & Ploemacher, R. (2000) · Leukemia · doi:10.1038/sj.leu.2401731 · Cited by 277
Rombouts, E. J. C., Pavic, B., Löwenberg, B., & Ploemacher, R. E. (2004) · Blood · doi:10.1182/blood-2004-02-0566 · Cited by 272
Metadata
- Authors
- Yokota, S., Hansen-Hagge, T., Ludwig, W., Reiter, A., Raghavachar, A., Kleihauer, E., & Bartram, C.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1991-01-15
- Volume
- 77
- Issue
- 2
- Pages
- 331-339
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2283795789
- Cited by
- 201
- References
- 1
- FWCI
- 41.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.